Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Fluticasone Propionate and Salmeterol Inhalation Powder, Placebo Inhalation Powder; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Asthma
Interventions: fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more

Conditions: Asthma
Interventions: Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas

Conditions: Asthma
Interventions: Placebo, FP 100mcg, FP 500mcg, FP 250mcg, FSC 100/50mcg, FSC 250/50mcg, FSC 500/50mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Asthma
Interventions: SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: Asthma
Interventions: Mometasone, Advair; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 11,751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 350
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more

Conditions: Asthma
Interventions: Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 50
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 42 more

Conditions: Asthma
Interventions: Fluticasone/Salmeterol Diskus, Fluticasone Diskus; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 19
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more

Conditions: Asthma
Interventions: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more

Conditions: Asthma
Interventions: QVAR, Advair, Servent Diskus; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COPD
Interventions: Placebo, Fluticasone /salmeterol; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 85
States / cities: Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: Allergic Asthma
Interventions: salmeterol, Fluticasone, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 58
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more

Conditions: Asthma
Interventions: Fp MDPI, FS MDPI, Advair Diskus, Albuterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 10
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Asthma
Interventions: Flovent Diskus, Home Environmental Intervention, Advair Diskus; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more

Conditions: COPD, COPD Exacerbation
Interventions: Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler; Device · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS™ 250/50mcg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more

Search by objective public record fields.

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

GSK BHR Study (Sont)

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Long-acting Beta Agonist Step Down Study

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

Non-invasive Measures of Distal Lung Disease in Asthmatics

Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

The Effect of Salmeterol on Eosinophil (EOS) Function

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Pharmacogenetics of b2-Agonists in Asthma.

Environmental Control as Add-on Therapy in Childhood Asthma

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)